세계의 세포 및 유전자 치료 시장

The global market for cell and gene therapy is expected to grow from $7.2 billion in 2023 and projected to reach $23.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 26.4% during the forecast period of 2023 to 2028. 

The global market for gene therapy is expected to grow from $2.9 billion in 2023 and projected to reach $10.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 28.7% during the forecast period of 2023 to 2028. 

The global market for gene modified cell therapy is expected to grow from $3.2 billion in 2023 and projected to reach $10.0 billion by the end of 2028, at a compound annual growth rate (CAGR) of 25.6% during the forecast period of 2023 to 2028.

Report Scope:

The scope of this study encompasses an investigation of the cell and gene therapy market. BCC Research analyzes cell and gene therapy market based on therapy type, product, application, and region. BCC determines the current market status in each segment, examines its impact on future needs, and presents growth forecasts over the next five years. The report provides a detailed analysis of the market's drivers, challenges, and opportunities. The report also covers market projections for 2028 and market shares for key market players. The report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides information on the emerging technologies, and new developments, ESG development and investment outlook.

Report Includes:

• 55 data tables and 26 additional tables
• An overview of the global market for cell and gene therapy
• Analysis of global market trends, featuring historical revenue data for 2020, 2021, and 2022, estimated figures for 2023, forecasts for 2028, and projections of compound annual growth rates (CAGRs) through 2028
• Evaluation of the current market's size and revenue growth prospects specific to cell and gene therapy, along with a market share analysis by therapy type, product, application, and geographic region
• An update on recent advances in vector biology, drug delivery technology and gene editing technologies such as CRISPR
• Coverage of novel therapeutic products and promising new technologies still in the development and testing stage, with as assessment of the probability that they will be commercialized successfully in the next five years
• Discussion on recent approvals, developments, emerging technologies, ESG, and an investment outlook
• Profiles of leading market participants, including Mallinckrodt PLC, Vericel Corp., Gilead Sciences Inc., Pharmicell Co. Ltd., and Bristol-Myers Squibb Co.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Value

Chapter 2 Market Overview

• Cell and Gene Therapy Overview
• Regulatory Landscape
• U.S. (FDA)
• Europe

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Market Restraints
• Market Opportunities

Chapter 4 Market Segmentation Analysis

• Segmentation Breakdown
• Global Market for Cell and Gene Therapy
• Market Size and Forecast
• Market Analysis
• Cell Therapy
• Gene-modified Cell Therapy
• Gene Therapy
• Global Market for Gene-modified Cell Therapy and Gene Therapy by Vector Type
• Market Size and Forecast
• Market Analysis
• Adeno-Associated Viral (AAV) Vectors
• Retroviral Vectors
• Lentiviral Vectors
• Others
• Global Market for Cell and Gene Therapy by Drug Product
• Market Size and Forecast
• Zolgensma
• Yescarta
• Kymriah
• Abecma
• Maci
• Tecartus
• Epicel
• Others
• Global Market for Cell and Gene Therapy by Application
• Market Size and Forecast
• Oncology
• Rare Diseases
• Ophthalmology
• Other Therapeutic Areas
• Geographic Breakdown
• Global Market for Cell and Gene Therapy by Region
• Market Size and Forecast
• North America
• Market Size and Forecast
• U.S.
• Canada
• Mexico
• Europe
• Market Size and Forecast
• Germany
• U.K.
• France
• Rest of Europe
• Asia-Pacific
• Market Size and Forecast
• Japan
• Cina
• Australia
• Rest of Asia-Pacific
• Rest of the World
• Market Size and Forecast

Chapter 5 Competitive Intelligence

• Investment Outlook
• Mergers and Acquisitions
• Competitive Landscape: Overview
• Market Share Analysis
• Strategic Acquisitions and Collaborations
• Pipeline Analysis

Chapter 6 Sustainability: An ESG Perspective

• Introduction
• Conclusion

Chapter 7 Appendix

• Methodology
• Company Profiles
• AMGEN INC.
• BLUEBIRD BIO INC.
• BRISTOL-MYERS SQUIBB CO.
• DENDREON PHARMACEUTICALS LLC
• FERRING PHARMACEUTICALS
• GILEAD SCIENCES INC.
• IOVANCE BIOTHERAPEUTICS INC.
• JOHNSON & JOHNSON SERVICES INC.
• KRYSTAL BIOTECH INC.
• MALLINCKRODT PLC
• NOVARTIS AG
• ORCHARD THERAPEUTICS PLC.
• PHARMICELL CO. LTD.
• UNIQURE N.V.
• VERICEL CORP.
• Abbreviations
• References